Bookmark and Share

Compound Summary for: CID 5291     Try the new version summary page

imatinib

Also known as: 152459-95-5; sti-571; STI571; Cgp 57148; STI 571; UNII-BKJ8M8G5HI; 1iep; 1xbb; Imatinib free base
Molecular Formula: C29H31N7O   Molecular Weight: 493.60274   InChIKey: KTUFNOKKBVMGRW-UHFFFAOYSA-N
Imatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells.   From: DrugBank
Show subcontent titlesTable of Contents
Identification
Related Records
show first sub-section only
Use and Manufacturing
Pharmacology
Literature
Patents
Biomolecular Interactions and Pathways
Biological Test Results
Classification
Chemical and Physical Properties
_ _